Overview
PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist derived from the naturally occurring peptide α-MSH (alpha-melanocyte-stimulating hormone). Unlike conventional approaches that primarily target vascular mechanisms, PT-141 works centrally through the nervous system — specifically activating MC3R and MC4R receptors in the hypothalamus — to support sexual motivation, arousal, and desire at the neurological level.
Clinically studied and backed by peer-reviewed research, PT-141 has demonstrated efficacy in both men and women, making it one of the most versatile and well-researched peptides in the human performance and wellness space. Each vial contains 10mg of lyophilized PT-141 peptide, manufactured to research-grade purity standards, and includes pharmaceutical-grade BAC water for reconstitution.
Designed for serious wellness optimizers, biohackers, and individuals focused on holistic vitality, PT-141 is a premium-grade compound for those who approach performance and wellbeing with precision and intention.
Key Benefits
- Central Nervous System Activation: Works through melanocortin receptors in the brain rather than peripheral vascular pathways — a fundamentally different and more targeted mechanism.
- Supports Sexual Motivation and Desire: Studied in both men and women for its role in supporting libido, arousal, and intimate connection at the neurological level.
- Promotes Psychological Wellbeing: Melanocortin pathways are also associated with mood, energy, and motivation — users often report a general sense of enhanced vitality.
- Complementary to Other Wellness Protocols: Integrates well into broader longevity, hormone optimization, and biohacking protocols without interfering with vascular function.
- Extensively Researched: Backed by multiple clinical trials and peer-reviewed publications, with a well-characterized receptor-binding profile.
- Fast-Acting Profile: Research indicates onset typically within 30–60 minutes post-administration, with effects lasting several hours.
- Flexible Dosing: Individual sensitivity varies — clinical studies have explored a range of dosing strategies, allowing for personalized optimization.
Popular Use Cases
- Individuals exploring peptide-based approaches to sexual wellness and intimate vitality
- Biohackers and longevity-focused users optimizing multiple dimensions of human performance
- Those seeking a neurologically-targeted alternative to conventional approaches
- Men and women on hormone optimization protocols looking to complement their existing stack
- Wellness professionals and researchers studying melanocortin system modulation
- Individuals interested in the intersection of neuroscience, motivation, and intimate wellbeing
Product Details
- Peptide: PT-141 (Bremelanotide)
- Dosage per Vial: 10mg lyophilized powder
- Format: Single vial — research-grade lyophilized peptide
- BAC Water Included: Yes — pharmaceutical-grade bacteriostatic water for reconstitution
- Storage: Store lyophilized peptide at 2–8°C (refrigerated). Once reconstituted, store at 2–8°C and use within 28 days.
- Purity: ≥99% (research grade)
- Origin: Manufactured under strict quality control — intended for research and wellness use
Invest in Your Vitality
PT-141 represents a convergence of neuroscience and human performance optimization — a precision tool for those who understand that true vitality encompasses every dimension of the human experience. Whether you’re building a comprehensive wellness protocol or exploring the cutting edge of peptide science, PT-141 10mg stands as one of the most well-researched, clinically-studied, and refined compounds available.
Formulated for the serious optimizer. Backed by science. Designed for those who refuse to leave any aspect of their wellbeing to chance.
Frequently Asked Questions
What is PT-141 and how does it differ from other sexual wellness peptides?
PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist that works centrally through the nervous system — specifically through MC3R and MC4R receptors in the hypothalamus. Unlike PDE5 inhibitors (such as sildenafil) which primarily target vascular mechanisms, PT-141 activates desire and arousal at the neurological level. This makes it effective in contexts where vascular-targeted compounds may be less suitable, and it is one of the few peptides studied for sexual motivation in both men and women.
How does PT-141 work in the body?
PT-141 binds to melanocortin receptors — primarily MC3R and MC4R — located in regions of the brain associated with sexual function, motivation, and emotional processing, particularly the hypothalamus. This activation triggers downstream signaling pathways that support sexual arousal and desire. The mechanism is distinct from vascular approaches: rather than increasing blood flow to peripheral tissues, PT-141 modulates the central neurological signals that initiate and sustain arousal.
Is PT-141 suitable for both men and women?
Yes. PT-141 has been studied in clinical trials involving both men and women. Its central mechanism of action — working through brain-based melanocortin receptors rather than sex-hormone-dependent pathways — makes it relevant to both sexes. Research has demonstrated effects on sexual desire and arousal in both male and female subjects, distinguishing it from many other compounds in this space.
What does the 10mg vial contain and what is included?
Each PT-141 vial contains 10mg of lyophilized (freeze-dried) Bremelanotide peptide, manufactured to ≥99% purity under strict quality control standards. The product includes pharmaceutical-grade bacteriostatic water (BAC water) for reconstitution. Once reconstituted, the solution should be stored at 2–8°C and used within 28 days. The lyophilized powder form ensures maximum stability and shelf life prior to reconstitution.
How quickly does PT-141 take effect?
Based on clinical research, PT-141 typically demonstrates onset within 30–60 minutes following subcutaneous administration. The active window in most studies ranges from 6 to 12 hours, depending on individual sensitivity, dose, and administration timing. Individual responses vary, and researchers exploring personalized protocols often begin with conservative doses to assess individual sensitivity before optimizing further.
Can PT-141 be combined with other peptides or wellness protocols?
PT-141 operates through a distinct receptor pathway (melanocortin system) that is largely independent of many other peptide mechanisms. It is frequently discussed in the context of broader biohacking and longevity stacks — particularly alongside hormone optimization protocols, BPC-157 for recovery support, and longevity peptides such as Epithalon. Its vascular-neutral mechanism means it does not interfere with compounds targeting metabolic or tissue repair pathways, making it a versatile addition to comprehensive wellness protocols.
What is the recommended storage protocol for PT-141?
Lyophilized PT-141 peptide should be stored at 2–8°C (standard refrigerator temperature) in a sterile, light-protected environment. Avoid exposure to direct sunlight, excessive heat, or repeated freeze-thaw cycles. Once reconstituted with bacteriostatic water, the solution should be refrigerated and used within 28 days for optimal stability. For long-term storage of unreconstituted vials beyond several months, some researchers prefer −20°C freezer storage.
Is PT-141 the same as Bremelanotide?
Yes. PT-141 is the research designation for Bremelanotide — the INN (International Nonproprietary Name) assigned to this compound. The peptide was originally derived from Melanotan II during research at University of Arizona, with subsequent development focusing on its sexual function applications. PT-141 refers to the investigational name used throughout the research and peptide community, while Bremelanotide is the clinical/pharmaceutical designation for the same molecule.
What makes PT-141 a premium wellness peptide compared to alternatives?
Several factors distinguish PT-141 in the peptide wellness space: its unique central nervous system mechanism (brain-based vs. vascular-based action), its applicability to both sexes, its extensive clinical research background including completed Phase III trials, its non-interference with cardiovascular function, and its specificity for melanocortin receptor subtypes associated with sexual motivation. For wellness optimizers seeking a well-characterized, neurologically-targeted compound, PT-141 represents a scientifically grounded choice with a robust research foundation.
Where can I learn more about the research behind PT-141?
The research literature on PT-141/Bremelanotide spans multiple decades and institutions. Key publications include Phase II and Phase III clinical trials published in peer-reviewed journals such as the Journal of Sexual Medicine and Obstetrics & Gynecology. The FDA approval of Vyleesi® (Bremelanotide injection) for hypoactive sexual desire disorder in premenopausal women in 2019 represents the most significant regulatory validation of this compound’s mechanism and safety profile. A curated selection of key references is provided in the Research References section below.
Research References
- Clayton, A.H., et al. (2016). “Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial.” Women’s Health, 12(3), 325–337. PubMed
- Diamond, L.E., et al. (2004). “Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist.” International Journal of Impotence Research, 16(1), 51–59. PubMed
- Molinoff, P.B., et al. (2003). “PT-141: A Melanocortin Agonist for the Treatment of Sexual Dysfunction.” Annals of the New York Academy of Sciences, 994, 96–102. PubMed
- Safarinejad, M.R., & Hosseini, S.Y. (2008). “Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.” Journal of Urology, 179(3), 1066–1071. PubMed
- Kingsberg, S.A., et al. (2019). “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder.” Obstetrics & Gynecology, 134(5), 899–908. PubMed
- Simon, J.A., et al. (2014). “Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder.” Journal of Sexual Medicine, 11(5), 1369–1381. PubMed
- Rosen, R.C., et al. (2004). “Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.” International Journal of Impotence Research, 16(2), 135–142. PubMed
- U.S. Food & Drug Administration (2019). “FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women.” FDA News Release. FDA.gov
- Pfaus, J.G., et al. (2007). “The melanocortins: from peptide ligands to melanocortin receptors.” European Journal of Pharmacology, 579(1–3), 1–7. PubMed
- Shadiack, A.M., et al. (2007). “Melanocortins in the treatment of male and female sexual dysfunction.” Current Topics in Medicinal Chemistry, 7(11), 1137–1144. PubMed
Reviews
There are no reviews yet.